Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2006 June;31(2) > Minerva Endocrinologica 2006 June;31(2):125-31

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383


eTOC

 

  CLINICAL ADVANCES IN DIABETES MELLITUS


Minerva Endocrinologica 2006 June;31(2):125-31

Copyright © 2006 EDIZIONI MINERVA MEDICA

language: English

The clinical utility of leptin therapy in metabolic dysfunction

Park J. Y., Gavrilova O., Gorden P.

National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health, Bethesda, MD, USA


PDF  


Obesity and diabetes are major public health threats worldwide. Insulin resistance appears to be a significant factor in this global epidemic. In this present review, we have focused on a human model of insulin resistance which embodies many of the metabolic abnormalities that are associated with the morbidity of diabetes and obesity. Lipodystrophy in rodents and humans is a severe model of insulin resistance, and we use a novel therapeutic approach with the administration of the newly discovered leptin to ameliorate many of these metabolic abnormalities. The ability to study the administration of leptin in this setting of severe insulin resistance allows us perform a coveted look into a human condition where metabolic dysfunction can be reversed or controlled.

top of page

Publication History

Cite this article as

Corresponding author e-mail